百合股份(603102) - 2021 Q4 - 年度财报

Financial Performance - The company's revenue for 2021 reached ¥661,874,435.29, representing a 14.45% increase compared to ¥578,287,203.18 in 2020[24]. - Net profit attributable to shareholders was ¥148,039,239.10, up 16.46% from ¥127,115,910.01 in the previous year[24]. - The net cash flow from operating activities was ¥169,149,696.97, reflecting a 12.77% increase from ¥149,997,634.85 in 2020[24]. - Total assets at the end of 2021 amounted to ¥915,918,074.40, a 25.84% increase from ¥727,851,850.89 in 2020[24]. - The company's net assets attributable to shareholders increased by 23.04% to ¥713,716,609.84 from ¥580,077,370.74 in 2020[24]. - Basic earnings per share for 2021 were ¥3.08, a 16.23% increase from ¥2.65 in 2020[25]. - The weighted average return on equity was 23.10%, down 1.15 percentage points from 24.25% in 2020[25]. - The company reported a net profit of ¥134,434,185.38 after deducting non-recurring gains and losses, which is a 14.62% increase from ¥117,291,383.17 in 2020[24]. - The diluted earnings per share also stood at ¥3.08, consistent with the basic earnings per share[25]. - The company achieved an operating revenue of 661.87 million RMB in 2021, representing a year-on-year growth of 14.45%[69]. - The net profit attributable to shareholders reached 148.04 million RMB, with a year-on-year increase of 16.46%[69]. Dividend Distribution - The company plans to distribute a cash dividend of 5 RMB per 10 shares, totaling 32 million RMB, which accounts for 21.62% of the net profit attributable to ordinary shareholders[4]. - The company has established a cash dividend policy, ensuring at least 10% of distributable profits are allocated for cash dividends[139]. - For the 2021 fiscal year, the proposed cash dividend is 5 RMB per 10 shares, pending approval from the shareholders' meeting[139]. - The cash dividend distribution plan aligns with the company's commitment to return at least 10% of distributable profits to shareholders annually, as per the A-share listing regulations[142]. Research and Development - The company's R&D investment in 2021 was 24.06 million yuan, accounting for 3.64% of operating income, representing a 15.98% increase from the previous year[34]. - The company holds 25 invention patents and 71 health food approval certificates, indicating strong R&D capabilities[59]. - The number of R&D personnel is 133, accounting for 13.50% of the total workforce, with 8 holding master's degrees and 41 holding bachelor's degrees[83]. - Research and development expenses amounted to 24,059,232.88 yuan, representing 3.64% of total operating revenue, with a year-on-year increase of 15.98%[82]. Market and Product Development - The company aims to enhance its product structure by developing infant supplementary foods, sports nutrition products, and specialized medical formula foods[40]. - The company plans to enhance the development of infant supplementary foods and sports nutrition products to strengthen its competitive advantage[65]. - The company plans to establish regional marketing centers in key cities across the country in 2022 to deepen customer demand and enhance service capabilities[35]. - The company aims to accelerate the development of its international market while expanding its domestic market presence in 2022[35]. - The company focuses on new product development and technological innovation to enhance competitiveness and adapt to market needs[36]. Corporate Governance - The board of directors guarantees the authenticity, accuracy, and completeness of the annual report[9]. - The company has implemented measures to ensure compliance with corporate governance standards, aligning with the Company Law and relevant regulations[119]. - The total pre-tax remuneration for the board members and senior management amounted to CNY 7.95 million in 2021, with no changes in shareholding during the reporting period[122]. - The company has a compensation and assessment committee responsible for formulating and reviewing the compensation policies for directors and senior management[126]. - The company has maintained effective internal controls over financial and non-financial reporting, with no significant deficiencies reported[148]. Risks and Challenges - The company has detailed potential risks in the report, urging investors to be cautious[10]. - The company faces risks related to product quality and food safety, which could impact its reputation and sales if not managed properly[109]. - Regulatory changes in food safety laws may significantly affect the long-term development and competitive landscape of the health food industry[110]. - The ongoing COVID-19 pandemic has posed challenges to the company's operations, affecting procurement, production, and sales channels[113]. Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 46, compared to 11,251 at the end of the previous month before the annual report disclosure[192]. - The top shareholder, Liu Xinli, holds 26,198,803 shares, representing 40.94% of the total shares[195]. - The second largest shareholder, Guangfa Xinde Investment Management Co., Ltd., holds 2,500,000 shares, accounting for 3.91%[195]. - Liu Xinli's shares are subject to a lock-up period until January 26, 2025, while Guangfa Xinde's shares are locked until January 26, 2023[197]. Operational Highlights - The company has established a comprehensive production capability for various dosage forms, including soft capsules, hard capsules, tablets, powders, oral liquids, and bottled drinks[40]. - The company has a production capacity exceeding 3.7 billion units per year, showcasing its scale production advantage[60]. - The company has a well-established marketing network covering over 30 provinces and regions in China, and its products are sold in more than 70 countries[68]. - The company operates in the nutrition and health food industry, benefiting from national policies promoting health and nutrition, which create a favorable environment for growth[39].